Participated · Seed · Jan 2026

Proxima (formerly VantAI) is building a platform that maps protein-protein interactions across the proteome and designs small-molecule drugs that modulate those interactions. Its NeoLink structural-proteomics system generates large-scale complex data, while the companion Neo AI model suite applies frontier machine-learning techniques to identify and design molecular glues, PROTACs, and other proximity-modulating compounds. The company focuses on expanding the druggable target space in oncology, immunology, and additional disease areas, aiming to improve safety and shorten development timelines for historically “undruggable” targets. Proxima has already secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines (now part of Sanofi), with the first co-developed program expected to enter clinical trials in 2026. It maintains both an internal pipeline and extensive external partnerships to advance novel proximity therapeutics. Financially, the firm closed an oversubscribed $80 million seed round and benefits from the non-dilutive value of its large pharmaceutical collaborations. Headquartered in New York and Boston, Proxima is positioning its technology and data layer as foundational infrastructure for the next generation of AI-driven drug discovery.

Participated · Series A · Dec 2025

PsiThera integrates biophysics, advanced computational modeling, and mechanistic biology to identify biologically relevant protein states and design optimized oral therapeutics targeting immune and inflammatory conditions. The company’s platform is intended to uncover novel therapeutic opportunities that traditional discovery approaches overlook. By focusing on protein conformations, PsiThera aims to create drugs with improved selectivity and efficacy. The organization is led by CEO Eric Shaff alongside Woody Sherman, Ph.D. (Chief Innovation Officer), Camil Sayegh, Ph.D. (Chief Scientific Officer), Jean-Christophe Harmange, Pharm.D., Ph.D. (SVP, Drug Discovery), and Kal Lapan, Ph.D. (VP, Head of Operations). The business plans to channel new capital into expanding its operations and advancing drug-development programs. PsiThera’s most recent financing—its $47.5 million Series A—provides the company’s current financial footing and resources for further growth.

Led · Seed · Feb 2025

Zest Health offers a virtual care platform that combines telemedicine with data-driven treatment plans for patients suffering from chronic inflammatory skin conditions such as psoriasis and eczema. By leveraging patient data, the company tailors prescription regimens, over-the-counter products, lifestyle recommendations, and preventative interventions to deliver more durable symptom relief. Its model targets convenience and responsiveness, aiming to reduce the need for in-person dermatology visits and improve long-term outcomes. The company works directly with health plans and employers, embedding its service into existing benefits programs. Proceeds from its latest funding will be used to scale these partnerships and expand access to its platform. Although no detailed operating metrics (e.g., revenue or user counts) were disclosed, the sizable seed raise signals early traction and confidence from its lead investor.

Participated · Equity · Dec 2022

Headquartered in New York, Lokavant offers a Clinical Trial Intelligence Platform that aggregates real-time and historical trial data to power predictive analytics and operational applications. The platform leverages a proprietary data asset covering more than 2,000 studies, 14,000+ investigators, and 12,000 healthcare institutions alongside integrated real-world data. Lokavant says its analytics drive a 70x improvement in enrollment-forecast accuracy, over $1 million in cost savings from patient retention, and six months' time savings from detecting site noncompliance. The company recently launched a Study Planning solution and began a collaboration with a top-10 pharmaceutical customer. With plans to open an APAC headquarters in Tokyo, Lokavant is expanding into Japan and the broader Asia‑Pacific market with product localization and regional staffing support. Lokavant is a clinical intelligence platform that enables real-time integration and harmonization of clinical trial data for study planning and operations. The company aggregates and integrates real-time data from disparate trial data sources and powers advanced analytics using its compendium of proprietary trial data. Its suite of applications supports data-driven study planning, benchmarking, operational health assessments, risk detection, medical monitoring, and vendor oversight. Clinical researchers access the platform via use-case-specific applications to proactively plan and manage studies and surface insights. Lokavant plans to use the $21M in funding to scale its commercial teams and accelerate feature development for its platform. The company is led by CEO Rohit Nambisan and is based in Princeton, NJ.

Participated · Seed · Sep 2022

Gen-t Science is creating a large genetic and health database by sequencing genomes and following volunteers longitudinally to accelerate precision and preventive medicine. Its core work is population genomics, with a focus on underrepresented socioeconomic groups (classes C and D) to address diversity gaps in global genomic datasets. The startup partners with low-income clinic chain Dr. Consulta and with municipal governments (pilot work in Amazonas and São Paulo) to recruit participants. As of the article, Gen-t has recruited 7,000 participants, expects 10,000 by year-end, aims for 25,000 by 2024, and plans to sequence 200,000 Brazilian genomes by 2026; it reported sequencing 4,000 genomes by 2022. Volunteer enrolment runs at roughly 800–900 people per month. The company says legal and consent-related investments are substantial, and it plans to leverage private-sector scale to become an accelerator of radical innovation and eventually a biotech. Gen-t is collecting genomic data from Brazilian patients to enrich biotech and medical research with the country’s diverse population. Founded by Lygia da Veiga Pereira, the company partners with Dr. Consulta, a network of medical centers in São Paulo and Rio de Janeiro, and initially runs efforts across four clinics in São Paulo. After a soft launch in June, Gen-t has over 200 active participants and is currently recruiting people aged 45 and older. The company aims to enroll more than 200,000 participants and maintain contact with each over a five‑year period or longer. Gen-t plans to make its platform available to academia to broaden research on Brazil’s genetics. It raised 10 million Brazilian reais (about $2 million USD) in a pre‑seed funding round led by Eduardo Mufarej with participation from Armínio Fraga, Daniel Gold of QVT Financial LP and Roivant Sciences. The round's proceeds will be used to build technical teams and begin clinical research.